Cipla beats quarterly profit view on strong demand
The Hindu
Cipla beats profit estimates with strong demand for chronic condition drugs, faces supply chain issues for tumour drug.
Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday (May 13, 2025), helped by strong demand for its drugs used to treat chronic conditions, especially respiratory illnesses.
The company's consolidated net profit came in at ₹12.22 billion ($143.5 million) in the January-March period. Analysts, on average, expected ₹10.24 billion, per data compiled by LSEG.
Total revenue increased 9.2% to ₹67.3 billion.
Cipla's U.S. sales are usually driven by its tumour drug Lanreotide, its second-biggest revenue generator. However, the company had warned in October that certain supply chain issues related to the drug would last until the fourth quarter.
India's drugmakers that derive significant revenue from North America through their cheaper version of innovator drugs have been on edge following U.S. President Donald Trump's tariff threat.
The company, earlier this year, said that tariffs should not influence decisions at India's drug companies.
Cipla’s generic drug for cancer gets U.S. FDA nod
RBI plans ₹1 lakh crore OMO in December to boost liquidity amid upcoming tax payments, ensuring stability in the banking system.
IndiGo faces ongoing flight delays and cancellations due to technology issues, weather, and new crew rostering rules.
Stock markets experience volatility as investors await RBI's monetary policy amid foreign fund outflows and mixed global trends.
ED attaches assets worth ₹1,120 crore in Anil Ambani's Reliance Group case, totaling ₹10,000 crore amid money laundering probe.
Rupee rises 20 paise to 89.69 against the dollar as investors await RBI's monetary policy decision amidst market pressures.
Just nine Fugitive Economic Offenders (FEOs) owed Indian banks over ₹58,000 crore in principal and interest. To date, banks have recovered just over ₹19,000 crore — roughly 33% of the total dues.
Commerce Minister Piyush Goyal urges Indian businesses to seize opportunities in Russia's market, addressing talent shortages and trade demands.
Premiumisation is driving the growth in beauty and personal care industry in India and this segment is growing faster than the products made for the masses, industry executives said at Cosmoprof India 2025, a beauty & personal care industry event currently underway in Mumbai.
Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.
The Rupee appreciated by 19 paise to close at 89.96 against the U.S. dollar amid weak dollar index support.
India aims to expand its tea exports to China, highlighting diverse varieties like Darjeeling and Masala at a recent buyer-seller meet.
Stock markets rebound after four days of decline as Sensex rises 158 points, driven by tech and IT shares.
India reduces Russian oil imports by 38% in October 2025, marking the sharpest decline in value and volume yet.